ReviewPLoS neglected tropical diseases2011
The emerging story of disability associated with lymphatic filariasis: a critical review.
Review in PLoS neglected tropical diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Stigma and intersectionality: a systematic review of systematic reviews across HIV/AIDS, mental illness, and physical disability.BMC public health · 2018Pooled it
- Self-Care for Management of Secondary Lymphedema: A Systematic Review.PLoS neglected tropical diseases · 2016Pooled it
- Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.PLoS neglected tropical diseases · 2022Trial
- A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.PLoS neglected tropical diseases · 2021Trial
- Integrated strategies for controlling and eliminating Neglected Tropical Diseases in Sub-Saharan Africa: a review of approaches, challenges, and opportunities.Tropical diseases, travel medicine and vaccines · 2026Review
- Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal.PLOS global public health · 2026Article
- Social and healthcare-seeking experiences of people affected with lymphedema in Bangladesh.PLoS neglected tropical diseases · 2025Article
- Global insights can accelerate India's journey towards the elimination of lymphatic filariasis as a public health problem.BMJ global health · 2025Review
- Prevalence and patterns of multiple long-term conditions among lymphatic filariasis patients in Odisha, India: a community-based cross-sectional study.BMC public health · 2025Article
- Article
- Article
- Acceptability of mass drug administration for lymphatic filariasis in Baglung Municipality of Nepal: A mixed-method study.PLOS global public health · 2025Article
- Burden, knowledge and perception of lymphatic filariasis in resource - poor communities in north central Nigeria.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Subnational Projections of Lymphatic Filariasis Elimination Targets in Ethiopia to Support National Level Policy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Zambia: A Narrative Review of Success and Challenges in Lymphatic Filariasis Elimination.Tropical medicine and infectious disease · 2024Review
- Article
- Factors influencing participation of elderly population in mass drug administration for lymphatic filariasis: a cross-sectional study.Frontiers in pharmacology · 2024Article
- Factors associated with never treatment and acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana, 2021.PLOS global public health · 2024Article
- Stage-Dependent Increase of Systemic Immune Activation and CCR5Pathogens (Basel, Switzerland) · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, 40 million people live with the chronic effects of lymphatic filariasis (LF), making it the second leading cause of disability in the world. Despite this, there is limited research into the experiences of people living with the disease. This review summarises the research on the experiences of people living with LF disability. The review highlights the widespread social stigma and oppressive psychological issues that face most people living with LF-related disability. Physical manifestations of LF make daily activities and participation in community life difficult. The findings confirm the need for the Global Programme to Eliminate Lymphatic Filariasis (GPELF) to support morbidity management activities that address the complex biopsychosocial issues that people living with LF-related disability face.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.